Category Archives: Biochemistry

Biochemistry

Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame – Vanderbilt University News

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and University Professor of Pharmacology, Biochemistry and Chemistry

Craig Lindsley, the William K. Warren, Jr. Chair in Medicine and director of Vanderbilt Universitys Warren Center for Neuroscience Drug Discovery, will be inducted as a member of the 2021 class of theDivision of Medicinal Chemistry Hall of Fame. MEDI is a subunit of theAmerican Chemical Society, the worlds largest scientific society and the premier home ofchemistryprofessionals.

Lindsley, the youngest inductee to the Hall of Fame, was selected because of his contributions to the field of medicinal chemistry.

This is a huge, career-defining honor and an amazing group of medicinal chemists and drug discovery scientists amongst whom to be included. This is a tremendous acknowledgement of the WCNDDs work and influence in the medicinal chemistry field, said Lindsley, also University Professor of Pharmacology, Biochemistry and Chemistry. In all honesty, this honor belongs to all of my former and current colleagues from Lilly, Merck and the WCNDD. Medicinal chemistry is just one arm of successful drug discovery, and no one person can do this alone or take creditit is big team science.

Craig Lindsley is a great medicinal chemist whose impact has been recognized not only by his induction into the MEDI Hall of Fame but also by his recent appointment as editor in chief of theJournal of Medicinal Chemistry, the premier journal in the field, saidLawrence Marnett, dean of the School of Medicine Basic Sciences. He brings great credit to the Basic Sciences and to Vanderbilt, but his greatest legacy may be the contributions he is making to improving the lives of individuals suffering from neurological diseases and neuropsychiatric disorders.

Induction into the ACS Division of Medicinal Chemistry Hall of Fame is an acknowledgement by leaders in our field that an individual scientist has had a sustained and substantial impact on research, teaching or service to the division, saidJacob Schwarz, chair of the ACS Division of Medicinal Chemistry executive committee. Dr. Lindsley is a rare example of someone who embodies all three of these achievements: from his early career work in the pharmaceutical industry, to his current role as educator and research mentor and finally as an ad hoc member of the MEDI executive committee. Dr. Lindsley has become well-known in our scientific community thanks to his tireless efforts both as author and editor, advancing the field of neuroscience drug discovery through research and training and by being an active social media presence highlighting exciting new developments.

Other 2021 MEDI Hall of Fame inductees areEdward Roberts, professor of molecular medicine and Scripps Research, andAnabella Villalobos, medicinal chemist and senior pharmaceutical executive at Biogen. Inductees are selected annually from nominations submitted by MEDI members and who have previously received theEdward E.Smissman Award, theDivision of Medicinal Chemistry award, an ACSGlaxoSmithKline Alfred Burger Awardor anE. B. Hershberg Award.

The 2021 Hall of Fame inductees will be recognized at the ACS National Meeting in Atlanta on Aug. 22, 2021.

Original post:
Craig Lindsley named to Medicinal Chemistry Division of the American Chemical Society Hall of Fame - Vanderbilt University News

Biochemistry

Metabolomics Reagents Market to Witness Robust Expansion by 2028 with Top Key players like Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry …

The report scope furnishes vital statistics about the current Metabolomics Reagents market status and key companies. It analyzes the in-depth business by considering different aspects, directions for companies, and strategies in the industry. After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered.The report also summarizes the various types of Metabolomics Reagents Market factors that influence the market growth of particular product category type and market status for it. A detailed study of the Metabolomics Reagents Market has been done to understand the various applications of the usage and features of the product. Readers looking for scope of growth with respect to product categories can get all the desired information over here, along with supporting figures and facts.

The report additionally provides a PESTEL analysis along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Metabolomics Reagents market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

Top Key Companies:Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry, Beijing Strong Biotechnologies, Randox Laboratories Limited, Biosino, Luxcel Biosciences, Shenzhen Bioeasy Biotechnology, Pointe Scientific, Biovision, Abbott, Shenzhen Lvshiyuan Biotechnology, Thermo Fisher Scientific, Merck[PDF] Get Latest Sample Report of Global Metabolomics ReagentsMarket 2021-2028: https://www.lexisbusinessinsights.com/request-sample-220167

The report has segmented Market 2021?2028 into different components on the basis of products, Application, geography and end users wherever needed. With thorough analysis and detailed study of past, present and future market 2017?2028 conditions, the report is able to deliver factual and reliable information to the users.

By Region / Countries

Key questions answered in the report include:

Our Research Experts have made this insightful report on Metabolomics Reagentsmarket, which is available for user on the site of Market Research Vision. The report carries various factors and elements of the industry in picture, all around the globe, be it its potential or probable threat to its growth or simply the way and method of its functioning during covid-19.

Reasons for Buying this Report:

TABLE OF CONTENT:

1 Report Overview

2 Global Metabolomics Reagents Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2015-2028

14 Analyst?s Viewpoints/Conclusions

15 Appendix

Feel free with your queries to get a call from our research expert @ https://www.lexisbusinessinsights.com/request-sample-220167

About Lexis Business Insights Market Research:

Lexis Business Insights is one of the top resellers of market research reports, including market intelligence, data solutions, competitive positioning, and custom intelligence to an array of organizations globally. Our customer portfolio includes business organizations from fortune 500 companies, SME?s, start-ups, financial technology start-ups, and venture capitalists. We have an exhaustive database of market research reports provided by more than 20 leading publishers across different industry verticals.

We provide tailored solutions that can be utilized to solve business challenges and problems faced by organizations in different regions. Additionally, our bouquet of solutions assists enterprises in strategic planning and staying ahead of the competition while getting access to extensive market forecast and trend mapping over the future course of time. In addition to the market forecast and other vital components of the market analysis, our reports include in-depth micro-macro analysis of the market, which aids the customers in analyzing the market ecosystem, thus assisting in the existing and new players in the development of strategic plans.Contact Us:James(Key Account Manager)

US: +1 210 907 4145

6851 N Loop

1604 W San Antonio,

TX 78249

sales@lexisbusinessinsights.com

http://www.lexisbusinessinsights.com

Visit link:
Metabolomics Reagents Market to Witness Robust Expansion by 2028 with Top Key players like Kerafast, Nitto Boseki, BD, Beijing Leadman Biochemistry ...

Biochemistry

Biochemistry Analyser Market Projected to Show Strong Growth |Abbott, Agappe Diagnostics, Thermo Fisher Scientific, Rms, Horiba The Manomet Current -…

Infinity Business Insights has just released a new market research study named Global Biochemistry Analyser Market. The market research gives a comprehensive overview of the current and future phases of the Biochemistry Analyser market based on criteria such as significant sought-after events, research innovations, management strategies, market drivers, challenges and visions, and comprehensive industry subdivision and regional distribution.

This statistical data provides an in-depth Biochemistry Analyser Market study by taking into account several categories such as type, size, technology, and applications. To provide correct data, many exploratory approaches such as qualitative and quantitative analysis have been applied.

GET SAMPLE COPY of this report @ https://www.infinitybusinessinsights.com/request_sample.php?id=490661

Major industry Players: Abbott, Agappe Diagnostics, Thermo Fisher Scientific, Rms, Horiba, Siemens Healthcare, Labindia Instruments, Xylem Analytics, Microlab Instruments

The Biochemistry Analyser Market business inquiry recalls possible figures for the economy, creation, application facts, value trends. The market analysis divides the market by application type and topography in terms of interest and prices. According to the summary, the global Biochemistry Analyser market is expected to reach XX$ 2021-2027 by 2020, with a CAGR of XX%.

Biochemistry Analyser industry -By Application:

Biochemistry Analyser industry By Product:

GET 20% discount For Early Buyers @ https://www.infinitybusinessinsights.com/ask_for_discount.php?id=490661

This Biochemistry Analyser analysis provides the most recent Biochemistry Analyser industry statistics, taking into account the various effects of COVID-19-related sector disruptions and halts. The new COVID-19 pandemic is having a major impact on the overall international exchange and businesses of the Biochemistry Analyser industry.

Inquiry Before Buying @ https://www.infinitybusinessinsights.com/enquiry_before_buying.php?id=490661

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

Read more:
Biochemistry Analyser Market Projected to Show Strong Growth |Abbott, Agappe Diagnostics, Thermo Fisher Scientific, Rms, Horiba The Manomet Current -...

Biochemistry

Smaller, faster, stronger: NSF grant will help Tvrdy develop the electronics of the future – Communique

Each year, consumers demand more from their electronic devices smaller sizes, faster processing and better performance. As engineers scramble to meet these demands with standard silicon-based transistors, another school of thought has emerged: using carbon nanotubes.

The cylindrical molecules that make up carbon nanotubes look like rolled-up tubes of chicken wire under a microscope. Strong, flexible, lightweight, thermally conductive and chemically stable, nanotubes are useful for a wide range of electronic and biomedical purposes.

Indeed, they may represent the future of electronic devices. But its deceptively difficult to grow nanotubes pure enough for research, not to mention real-world applications. During the growth process, many different types of carbon nanotubes are produced, necessitating purification that has remained elusive for these otherwise promising materials.

Now, a $250,000 National Science Foundation grant will allow Kevin Tvrdy, associate professor of chemistry & biochemistry at UCCS, to advance the process of creating and purifying these molecules for the benefit of nanoscience worldwide.

Tvrdys proposal, titled Synthesis and Characterization of Novel Hydrogel Formulations for the Single Chirality Purification of Single-Walled Carbon Nanotubes, has a specific focus: creating hydrogels tailored for the purification of nanotubes, thereby helping to allow the scientific community to research and apply nanotubes at scale.

The advancement of carbon nanotube purification stands to enable the development of next-generation devices and schemes that take full advantage of nanotube properties, Tvrdy said. Some examples include the fabrication of ultrasmall carbon-based electronics, solar cells capable of harvesting the infrared region of the spectrum, and imaging schemes capable of simultaneously sensing and mapping with nanoscale precision.

In other words, the future of phones, wearable electronics, solar cells, biomedical devices and more could rest on the carbon nanotube purification schemes under development by researchers and developers like Tvrdy.

Tvrdy and his research team, consisting of graduate and undergraduate students, will work to devise different formulations of hydrogel that target specific properties within carbon nanotubes. By developing both high- and low-cost formulation of the gel, their hope is to expand the number of pure, single-walled carbon nanotube species available to the scientific community for research and applied use.

They will publicly report their research progress within the Colorado Springs Science on Tap lecture series and results from this work will be integrated into Tvrdys nanoscience.

And perhaps, in the near future, we will have Tvrdy and his team to thank for electronic devices that are smaller, faster and stronger than we ever imagined.

Kevin Tvrdy is an associate professor of chemistry & biochemistry within the College of Letters, Arts and Sciences at UCCS. His research interests lie in the synthesis, purification and characterization of low dimensional materials and their use in novel devices. Of particular interest are the optical and electronic properties of single walled carbon nanotubes and semiconducting quantum dots. Learn more about Tvrdy and the Tvrdy Lab at UCCS online.

Read the original:
Smaller, faster, stronger: NSF grant will help Tvrdy develop the electronics of the future - Communique

Biochemistry

Libraries to Receive $25000 Grant from National Endowment for the Arts – University of Arkansas Newswire

FAYETTEVILLE, Ark. The University of Arkansas Libraries have been approved for a $25,000 grant through the Grants for Arts Projects, which will support Arkansas Folk and Traditional Arts Community Scholars Program.

Arkansas Folk and Traditional Arts is a statewide outreach program of the University of Arkansas Libraries. This project will provide free training across the state centered on equipping and empowering Arkansas communities to document, present and sustain their traditional culture and arts.

As the country and the arts sector begin to imagine returning to a post-pandemic world, the National Endowment for the Arts is proud to announce funding that will help arts organizations such as Arkansas Folk and Traditional Arts reengage fully with partners and audiences, said Ann Eilers, acting chair for the National Endowment for the Arts. Although the arts have sustained many during the pandemic, the chance to gather with one another and share arts experiences is its own necessity and pleasure.

Arkansas Folk and Traditional Arts Community Scholars Program will be modeled after the Kentucky Arts Councils longstanding and successful training of the same name.

Arkansas Folk and Traditional Arts will host three trainings throughout the project year in different geographic regions of Arkansas in partnership with hosting organizations and/or individuals. Each training will include five sessions designed to introduce folklore and folk art, teach oral history and fieldwork skills and provide examples for how communities can archive or showcase their research.

The NEAs support will help us grow a network of Community Scholars across the state who are aligned with our own mission to document, present and sustain Arkansas rich cultural heritage, said Virginia Siegel, coordinator for Arkansas Folk and Traditional Arts. Community Scholars are already the experts of their communities and we hope this program will provide resources to strengthen these experts toolkits.

About Arkansas Folk and Traditional Arts:AFTA is a statewide folk arts program of the University of Arkansas Libraries dedicated to building cross-cultural understanding by documenting, presenting, and sustaining Arkansas living traditional arts and cultural heritage. AFTA is supported in part by the National Endowment for the Arts and works in partnership with stakeholder organizations and individuals, including the Arkansas Arts Council, Mid-America Arts Alliance, and Arkansas State University.

About the University Libraries: Located in the heart of campus, the David W. Mullins Library is the university's main research library. Branch libraries include the Chemistry and Biochemistry Library, the Fine Arts Library, the Physics Library, and the Robert A. and Vivian Young Law Library. The Libraries provide access to more than 3.1 million volumes and more than 180,000 journals and offer research assistance, study spaces, computer labs with printing and scanning, interlibrary loan and delivery services, and cultural exhibits and events. The Libraries' Special Collections division acquires, preserves, and provides access to materials on Arkansas and the region, its customs and people, and its cultural, physical, and political climate. Visit the Libraries' website at libraries.uark.edu to learn more about services and collections.

About the University of Arkansas: The University of Arkansas provides an internationally competitive education for undergraduate and graduate students in more than 200 academic programs.

Go here to see the original:
Libraries to Receive $25000 Grant from National Endowment for the Arts - University of Arkansas Newswire

Biochemistry

Bio-Based Itaconic Acid Market | Key Opportunities, Trends, Business Demand And Key Players Analysis | Itaconix Corporation, Qingdao Kehai…

Bio-Based Itaconic Acid Market report helps to Analys Market by critical success factors (CSFs) And industry dynamics that mainly covers drivers and restraints, market segmentation, & value chain analysis, key opportunities, application and technology outlook. The report also provides regional or geographical insight, country-level analysis, key company profiles, competitive landscape, and company market share analysis. This market research report deeply analyses the potential of the market with respect to current scenario and the future prospects by taking into view numerous industry aspects.

About Bio-Based Itaconic Acid Market:

Bio-based itaconic acid market is expected to grow at a rate of 5.50% for the forecast period of 2020 to 2027. Data Bridge Market Research report on bio-based itaconic acid market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecasted period while providing their impacts on the markets growth.The changing trend towards eco-friendly products due to growing awareness regarding green house emissions will help impact the bio-based itaconic acid market growth in the forecast period.

Download Free Sample Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bio-based-itaconic-acid-market

The Bio-Based Itaconic Acid Market report is an appropriate compilation of all necessary data for the residential, industrial and commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projectedalsobecause theprevailing trendswithin theBio-Based Itaconic Acid Market.

leadingPlayers Covered in Bio-Based Itaconic Acid Market Report :

The major players covered in the bio-based itaconic acid market report are Thermo Fisher Scientific., Itaconix Corporation, Qingdao Kehai Biochemistry Co., LTD., AEKYUNG PETROCHEMICAL Co., Ltd, Zhejiang Guoguang Biochemistry Co.,Ltd., Spectrum Ultimate Chem India Pvt. Ltd, Alpha Chemika, Haihang Industry Co., Ltd, Ronas Chemicals Ind. Co., Ltd., Hefei TNJ Chemical Industry Co.,Ltd., Alfa Aesar, Merck KGaA, Choice Organochem Llp., FUSO CHEMICAL CO., LTD., Henan Haofei Chemical Co.,Ltd., Chemical Manufacturing Corp and FUJIFILM Wako Pure Chemical Corporation, among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Key Questions Answered by the Report

Get More Insight Before Buying @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bio-based-itaconic-acid-market

This report makes it easy to know about the market strategies that are being adopted by the competitors and leading organizations.An influential business report also provides the understanding of the most affecting driving and restraining forces in the market and its impact on the global market.

Highlights of the Report:

Get Table of Contents with Charts, Figures & Tables @https://www.databridgemarketresearch.com/toc/?dbmr=global-bio-based-itaconic-acid-market

About Us:

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:

Data Bridge Market Research

Tel: +18883872818

corporatesales@databridgemarketresearch.com

Read the rest here:
Bio-Based Itaconic Acid Market | Key Opportunities, Trends, Business Demand And Key Players Analysis | Itaconix Corporation, Qingdao Kehai...

Biochemistry

Portable Veterinary Biochemistry Analyzer Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU | The Sentinel…

Global Portable Veterinary Biochemistry Analyzer Market report provides information on types, applications and its regional markets including past and expected Opportunities. Portable Veterinary Biochemistry Analyzer Market report delivers data on Manufacturers, Geographical Regions, Types, Applications, Key Drivers, Challenges, Opportunities, Annual Growth Rate, Market Share, Revenue and the actual process of whole Portable Veterinary Biochemistry Analyzer industry.

Request sample copy of this report at

https://www.researchforetell.com/reports/66698/portable-veterinary-biochemistry-analyzer-marketglobal-outlook-and-forecast-2021-2027/request

BEAT THE PANDEMIC WITH THE RESEARCH FORETELL (Download Complimentary Covid-19 document on Global Portable Veterinary Biochemistry Analyzer Market)

The scope of this research report extends from the basic outline of the Portable Veterinary Biochemistry Analyzer Market to tricky structures, classifications and applications. This research report also provides a clear picture of the global market by presenting data through effective information graphics. It also provides a detailed list of factors that affect market growth.

A detailed study of the competitive landscape of the Global Portable Veterinary Biochemistry Analyzer Market has been given along with the insights of the companies, financial status, trending developments, mergers & acquisitions and SWOT analysis. This research will give a clear and precise idea about the overall market to the readers to take beneficial decisions.

Inquire for discount at

https://www.researchforetell.com/reports/66698/portable-veterinary-biochemistry-analyzer-marketglobal-outlook-and-forecast-2021-2027/discount

This report contains market size and forecasts of Portable Veterinary Biochemistry Analyzer in global, including the following market information:

Global Portable Veterinary Biochemistry Analyzer Market Revenue, 2016-2021, 2022-2027, ($ millions)

Global Portable Veterinary Biochemistry Analyzer Market Sales, 2016-2021, 2022-2027, (K Units)

Global top five Portable Veterinary Biochemistry Analyzer companies in 2020 (%)

The global Portable Veterinary Biochemistry Analyzer market was valued at xx million in 2020 and is projected to reach US$ xx million by 2027, at a CAGR of xx% during the forecast period.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Portable Veterinary Biochemistry Analyzer manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Portable Veterinary Biochemistry Analyzer Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)

Global Portable Veterinary Biochemistry Analyzer Market Segment Percentages, By Type, 2020 (%)

Automatic

Semi-Automatic

Global Portable Veterinary Biochemistry Analyzer Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)

Global Portable Veterinary Biochemistry Analyzer Market Segment Percentages, By Application, 2020 (%)

Veterinary Hospitals

Veterinary Clinics

Others

Global Portable Veterinary Biochemistry Analyzer Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (K Units)

Global Portable Veterinary Biochemistry Analyzer Market Segment Percentages, By Region and Country, 2020 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Portable Veterinary Biochemistry Analyzer revenues in global market, 2016-2021 (Estimated), ($ millions)

Key companies Portable Veterinary Biochemistry Analyzer revenues share in global market, 2020 (%)

Key companies Portable Veterinary Biochemistry Analyzer sales in global market, 2016-2021 (Estimated), (K Units)

Key companies Portable Veterinary Biochemistry Analyzer sales share in global market, 2020 (%)

Further, the report presents profiles of competitors in the market, key players include:

EKF Diagnostics

Samsung

Randox

Alphatecscientific

Genrui

KPM Analytics(AMS Alliance)

Woodleyequipment

Idexx

Zoetis(Abaxis)

Seamaty

YSENMED

MNCHIP

Full Report:

https://www.researchforetell.com/reports/66698/portable-veterinary-biochemistry-analyzer-marketglobal-outlook-and-forecast-2021-2027

Key Features of the Report:

About Us

Research Foretell is an information service company that provides market research, custom, and consulting services. Decision-making is complicated and we help you to solve your biggest puzzle, by identifying, analyzing, and monitoring the recent developing technologies and markets. Research Foretell is always forefront on classifying new opportunity in the market; with us you always have the first mover advantage.

Contact Us:

Robert Claussen (Head of Sales)

Phone: +91-81499-24059

Email: sales@researchforetell.com

View post:
Portable Veterinary Biochemistry Analyzer Market Global Demand, Research and Top Leading Player to 2026 Covid-19 Analysis KSU | The Sentinel...

Biochemistry

Stablix Therapeutics Launches with $63 Million Series A Financing – BioSpace

--Versant Ventures leads investment in first-in-category company with targeted protein stabilization platform --

--Foundational know-how establishes leadership in the field--

NEW YORK--(BUSINESS WIRE)-- Stablix Therapeutics, a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS), today announced a $63 million Series A financing led by founding investor Versant Ventures together with NEA, Cormorant, Euclidean Capital and Alexandria Real Estate Equities.

Many inherited and acquired diseases are caused by insufficient levels of specific proteins. With inherited diseases such as cystic fibrosis, mutations in the CFTR gene produce a protein that remains functional but is subject to excessive ubiquitination, leading to its rapid degradation via the proteasome. Excess ubiquitination is also a feature of cancer, where E3 ubiquitin ligases enzymes that add ubiquitin to proteins are frequently upregulated or amplified, driving the degradation of tumor suppressor proteins.

Until now, it has not been possible to inhibit the ubiquitin-proteasome system in a target-selective manner. Stablixs RESTORED platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. The company initially is leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

Stablix possesses a first-in-category platform that can restore protein stability and function in a target-selective manner, said Carlo Rizzuto, Ph.D., partner at Versant and acting CEO of Stablix. We are very pleased to launch this company to address this important therapeutic white space for numerous devastating diseases.

Targeted Protein Stabilization (TPS)

Protein stabilization can be thought of as the inverse of protein degradation. The underlying concept of augmenting protein stabilization has been validated in nature. Many viruses encode their own E3 ligases and deubiquitinases to coopt the ubiquitin-proteasome system as part of their life cycles. This demonstrates that the system can be manipulated via exogenous intervention.

The therapeutic value of augmenting protein stabilization has also been demonstrated with proteasome inhibitors. These inhibitors are potent cancer therapeutics but have also been profiled for activity in Mendelian diseases in multiple animal and patient studies. In these studies, proteasome inhibitors were able to increase levels of deficient proteins across a range of targets and organ systems. However, because proteasome inhibitors globally inhibit protein degradation in a non-specific manner, their use outside of oncology is limited by poor tolerability, highlighting the need for targeted approaches.

The Stablix platform originated in the laboratory of Henry Colecraft, Ph.D., John C. Dalton Professor of Physiology and Cellular Biophysics at Columbia University. Co-founders Dr. Colecraft and Scott Kanner, Ph.D., developed an approach to selectively recruit deubiquitinases (DUBs) to proteins of interest. Their pioneering work demonstrated the functional rescue of CFTR and of a second target, KCNQ1, a gene that when mutated causes Long QT syndrome.

It is gratifying to see the work on precise stabilization of proteins now being translated into new therapies, said Dr. Colecraft. I look forward to working closely with the Stablix team to bring these treatments to patients.

The companys RESTORED platform has two primary components. The first is a library of binding moieties capable of recruiting selected DUBs. These recruiting moieties are conjugated with linkers to targeting ligands to create bispecific molecules that co-localize a DUB and a target. Second, a suite of biochemical and functional assays is used to monitor the ubiquitination and functional status of target proteins in cells. Stablix will initially focus pipeline development on rare diseases, oncology and immunology.

Operating plans and scientific leadership

Stablix plans to use the proceeds from the Series A financing to build out its platform and advance a portfolio of protein stabilizers towards the clinic. In addition, the company has established a lab facility in New York City, where it is building a research team led by co-founders Brian Bowman, Ph.D., head of in vitro pharmacology, and Kevin Sprott, Ph.D., head of drug discovery, with Dr. Kanner, head of platform development, leading technology transfer.

For its Scientific Advisory Board, Stablix has recruited a leading group of researchers with extensive experience in DUB biology and chemistry. In addition to Dr. Colecraft, SAB members include Benedikt Kessler, professor of biochemistry and mass spectrometry at the Target Discovery Institute, University of Oxford; Andrew Turnbull, senior principal scientist at Cancer Research UK; Chris Dinsmore, CSO at Kronos Bio; and Chris Roberts, CSO at Black Diamond Therapeutics.

Stablixs unique approach presents the company with a massive opportunity to create an impact for patients with rare diseases, cancer or immunological disorders, said Ali Behbahani, M.D., general partner at NEA and a Stablix board member. We are pleased to join this high-quality syndicate and look forward to the continued development of Stablixs platform and programs.

About Stablix Therapeutics

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS). The companys RESTORED platform generates heterobifunctional small molecules (RESTORACS) that recruit deubiquitinase enzymes to remove ubiquitin from targeted proteins and consequently stabilize or increase target protein levels and activity. Stablix initially is leveraging the platform to develop programs to treat rare diseases, cancer and immunological disorders.

About Versant Ventures

Versant Ventures is a leading healthcare venture capital firm committed to helping exceptional entrepreneurs build the next generation of great companies. The firms emphasis is on biotechnology companies that are discovering and developing novel therapeutics. With $4.2 billion under management and offices in the U.S., Canada and Europe, Versant has built a team with deep investment, operating and R&D expertise that enables a hands-on approach to company building. Since the firms founding in 1999, more than 85 Versant companies have achieved successful acquisitions or IPOs. For more information, please visit http://www.versantventures.com.

About NEA

New Enterprise Associates, Inc. (NEA) is a global venture capital firm focused on helping entrepreneurs build transformational businesses across multiple stages, sectors and geographies. With nearly $24 billion in cumulative committed capital since the firm's founding in 1977, NEA invests in technology and healthcare companies at all stages in a company's lifecycle, from seed stage through IPO. The firm's long track record of successful investing includes more than 230 portfolio company IPOs and more than 390 mergers and acquisitions. http://www.nea.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005184/en/

See the original post here:
Stablix Therapeutics Launches with $63 Million Series A Financing - BioSpace

Biochemistry

Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer – Business Wire

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a presentation by Memorial Sloan Kettering Cancer Center (MSK) at the upcoming annual meeting of the American Society of Clinical Oncology (ASCO) to discuss the Resolution ctDx Lung, a laboratory-developed test (LDT) developed by Resolution Bioscience.

The presentation titled Overall survival with circulating tumor DNA-guided therapy in advanced non-small cell lung cancer will present evidence for the clinical utility of Resolution ctDx Lung in detecting actionable mutations in non-small cell lung cancer (NSCLC) patients.

Previous findings have supported the clinical utility of the Resolution ctDx Lung for accurately selecting patients for targeted therapies.1 The latest study, involving the largest prospective liquid biopsy cohort (>1,000 patients) with 34 years of survival data, demonstrates that cell-free DNA guided targeted therapies help result in better overall survival.

This is the first and largest prospective study of ctDNA guided therapy to show an overall survival benefit in patients with lung cancers, providing evidence for the utility of liquid biopsy in clinical practice, said Bob Li, MD, PhD, MPH, Co-Director of the Thoracic Liquid Biopsy Program at MSK.

This large cohort highlights the utility of the Resolution ctDx Lung in helping guide therapy selection to improve patient outcomes, said Mark Li, CEO of Resolution Bioscience, now a part of Agilent. Significantly, the study highlighted important differences between liquid biopsies and tissue testing, including faster turnaround to reporting, while providing the benefits of guided targeted therapy."

The success of Resolution ctDx Lung further strengthens Agilent's ability to deliver precision oncology testing assays for patients worldwide and demonstrates the company's commitment as a partner in the development of powerful new clinical diagnostics solutions to expand the fight against cancer.

Resolution Bioscience is dedicated to developing a highly sensitive, non-invasive liquid biopsy platform that improves cancer diagnostics and monitoring for patients around the world. The company has developed core technology for circulating cell-free DNA NGS analysis. Resolution Biosciences Liquid Biopsy assays are powered by the companys cell-free DNA (cfDNA) analysis platform, which includes targeted capture next-generation sequencing (NGS) biochemistry and tightly coupled, cloud-based bioinformatics. The Resolution Bioscience homologous recombination deficiency (HRD) assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration.

References:

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at http://www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.

Read the original:
Cell-Free DNA Guided Targeted Therapy Leads to Better Survival in Advanced Non-Small Cell Lung Cancer - Business Wire

Biochemistry

Weight loss story: Here’s how this student used nutritional biochemistry to lose weight fast" | The Times of India – Times of India

I followed the principles of Intermittent Fasting for weight loss. I used to maintain a 16-hour gap between my dinner and brunch and then, a 6-hour gap between brunch and dinner.

My breakfast: I only have two glasses of warm water in the morning.

Even now, when I have achieved 4% body fat, I still follow the eating pattern, it's like a ritual for me. I feel it's the best way to keep our metabolism in shape, without starving or avoiding certain foods.

My lunch: I had to lose a considerable amount of fat so I had to keep a strict regime on my calories intake. With the knowledge of nutrition, I calculated that I needed 1500kcal/day to achieve the goal. So, I took 750kcal from my lunch and 750kcal from my dinner.

It consisted of 2 chapatis, 1 cup daal, 1 cup of green vegetables and 100 gm of unpolished rice. I never believed in the concept that carbs are harmful for weight loss. Each macro is important and equally beneficial, we just have to create a balance in our input.

My dinner: 2 chapatis, 1 cup daal, green veggies and 1 glass of unsweetened milk at the time of going to bed.

Pre-workout meal: A cup of black coffee with no sugar.

Post-workout meal: After the workout, I just hydrate my body so that it can utilize all the fat oxidation properly.

I indulge in (What you eat on your cheat days): I used to have non-veg food on cheat days. I ate chicken curry, fish on my cheat days. Also, I took higher calories by 300kcal on these days. A regulated cheat day is very helpful in balancing the set point of the metabolism.

Low-calorie recipes I swear by: Daal is best for our body. It not only helps in Ketosis but also keeps us full for a longer time.

Read the original here:
Weight loss story: Here's how this student used nutritional biochemistry to lose weight fast" | The Times of India - Times of India